Comparative Pharmacology
Head-to-head clinical analysis: ETIDRONATE DISODIUM versus ZOLEDRONIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETIDRONATE DISODIUM versus ZOLEDRONIC ACID.
ETIDRONATE DISODIUM vs ZOLEDRONIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, suppressing crystal dissolution and reducing bone turnover.
Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway.
Paget disease: 5-10 mg/kg/day orally, given as a single dose or divided every 12 hours, for up to 6 months; or 300 mg intravenously over at least 2 hours daily for 3 days. Heterotopic ossification: 20 mg/kg/day orally for 2 weeks pre- and 12 weeks post-surgery. Hypercalcemia of malignancy: 7.5 mg/kg intravenously over 4 hours daily for 3-7 days.
5 mg intravenously over at least 15 minutes once yearly for Paget disease or osteoporosis; 4 mg intravenously over at least 15 minutes every 3-4 weeks for hypercalcemia of malignancy or multiple myeloma/bone metastases.
None Documented
None Documented
Clinical Note
moderateZoledronic acid + Deferasirox
"The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Deferasirox."
Clinical Note
moderateTiaprofenic acid + Zoledronic acid
"The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zoledronic acid."
Clinical Note
moderateCarprofen + Zoledronic acid
"The risk or severity of adverse effects can be increased when Carprofen is combined with Zoledronic acid."
Clinical Note
moderateTerminal half-life: 1-6 hours after single dose; prolonged to up to 2 weeks in bone due to slow release from hydroxyapatite.
Terminal half-life is approximately 146 hours (6 days), reflecting slow release from bone; clinical effect persists beyond this due to prolonged binding to hydroxyapatite.
Renal: 30-50% of absorbed dose excreted unchanged in urine; biliary/fecal: minimal, with approximately 5% excreted in feces.
Primarily renal (30-40% unchanged in urine over 24h, accounting for ~50% of total clearance); negligible biliary or fecal elimination (<1%).
Category C
Category D/X
Bisphosphonate
Bisphosphonate
Thalidomide + Zoledronic acid
"The risk or severity of adverse effects can be increased when Thalidomide is combined with Zoledronic acid."